NervGen Pharma Corp. (NGEN.V)
CAD 2.46
(-7.17%)
CAD 2.46
(-7.17%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 145 Thousand | 115.11 Thousand | 42.62 Thousand | 39.64 Thousand | 38.22 Thousand | 19.76 Thousand |
| Gross Profit | -145 Thousand | -115.11 Thousand | -42.62 Thousand | -39.64 Thousand | -38.22 Thousand | -19.76 Thousand |
| Operating Expenses | 17.77 Million | 23.02 Million | 12.81 Million | 11.19 Million | 9.86 Million | 1.35 Million |
| Selling, General and Administrative Expenses | 9.73 Million | 6.33 Million | 5.93 Million | 5.03 Million | 3.37 Million | 578.08 Thousand |
| Research and Development Expenses | 7.99 Million | 16.61 Million | 6.87 Million | 6.16 Million | 6.44 Million | 780.4 Thousand |
| Other Expenses | - | 73.36 Thousand | 2054.00 | 1425.00 | 38.22 Thousand | - |
| Cost and Expenses | 17.77 Million | 23.02 Million | 12.81 Million | 11.19 Million | 9.86 Million | 1.35 Million |
| Operating Income | -17.77 Million | -22.82 Million | -12.86 Million | -11.18 Million | -9.86 Million | -1.35 Million |
| Interest Expense | - | 514.59 Thousand | - | - | - | - |
| Income Tax Expense | - | -2.61 Million | -84.64 Thousand | -9743.00 | -98.82 Thousand | -141.37 Thousand |
| Earnings before Tax | -22.38 Million | -20.72 Million | -12.72 Million | -11.18 Million | -9.76 Million | -1.35 Million |
| Net Income | -22.38 Million | -18.1 Million | -12.64 Million | -11.17 Million | -9.66 Million | -1.35 Million |
| Earnings Per Share Basic | -0.38 | -0.34 | -0.32 | -0.35 | -0.37 | -0.05 |
| Earnings Per Share Diluted | -0.38 | -0.34 | -0.32 | -0.35 | -0.37 | -0.05 |
| Weighted Average Shares Outstanding | 59.29 Million | 52.64 Million | 39.28 Million | 32.11 Million | 25.9 Million | 27.2 Million |
| Weighted Average Shares Outstanding (Diluted) | 59.29 Million | 52.64 Million | 39.28 Million | 32.11 Million | 25.9 Million | 27.2 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -17.72 Million | -20.09 Million | -12.76 Million | -11.15 Million | -9.82 Million | -1.33 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 15.02 Thousand | 38.3 Thousand | 38.62 Thousand | 145 Thousand | 36.62 Thousand | 34.99 Thousand |
| Gross Profit | -15.02 Thousand | -38.3 Thousand | -38.62 Thousand | -145 Thousand | -36.62 Thousand | -34.99 Thousand |
| Operating Expenses | 6 Million | 5 Million | 4.83 Million | 17.63 Million | 3.41 Million | 4.76 Million |
| Selling, General and Administrative Expenses | 2.2 Million | 2 Million | 2.18 Million | - | 2.55 Million | 3.22 Million |
| Research and Development Expenses | 3.8 Million | 3 Million | 2.65 Million | - | 837.57 Thousand | 1.51 Million |
| Other Expenses | 1080.00 | - | - | - | - | - |
| Cost and Expenses | 6 Million | 5 Million | 4.87 Million | 17.77 Million | 3.41 Million | 4.76 Million |
| Operating Income | -6 Million | -5 Million | -4.87 Million | -17.77 Million | -3.27 Million | -4.63 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 7.8 Million | 2.3 Million | -3.00 | -3.00 | 76.21 Thousand | -7473.00 |
| Earnings before Tax | -7.82 Million | -2.34 Million | -8.6 Million | -22.38 Million | -4.3 Million | -4.76 Million |
| Net Income | -7.8 Million | -2.3 Million | -8.6 Million | -22.38 Million | -4.3 Million | -4.76 Million |
| Earnings Per Share Basic | -0.13 | -0.04 | -0.14 | - | -0.07 | -0.08 |
| Earnings Per Share Diluted | -0.13 | -0.04 | -0.14 | - | -0.07 | -0.08 |
| Weighted Average Shares Outstanding | 60.2 Million | 60.2 Million | 59.6 Million | 59.29 Million | 59.41 Million | 59.21 Million |
| Weighted Average Shares Outstanding (Diluted) | 60.2 Million | 60.2 Million | 59.6 Million | 59.29 Million | 59.41 Million | 59.21 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -13.8 Million | -7.45 Million | -4.83 Million | - | -3.24 Million | -4.6 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
NFAZ
EXRO
002302
002040
CSW-A
PRADPME